A one year extension study to CZOL446H2337, multi-center, to evaluate safety and efficacy of zoledronic acid given to all patients every six months in children with weakened bone treated with steroids

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020399-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids.


Critère d'inclusion

  • Treatment of osteoporosis in a paediatric population (aged 5 to 19 years old) treated with systemic glucocorticoids (i.v. or oral)

Liens